tiprankstipranks
Achieve Life Sciences Inc (ACHV)
NASDAQ:ACHV

Achieve Life Sciences (ACHV) Stock Forecast & Price Target

1,031 Followers
See the Price Targets and Ratings of:

ACHV Analyst Ratings

Moderate Buy
2Ratings
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Achieve
Life Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ACHV Stock 12 Months Forecast

Average Price Target

$20.50
▲(351.54% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Achieve Life Sciences in the last 3 months. The average price target is $20.50 with a high forecast of $30.00 and a low forecast of $11.00. The average price target represents a 351.54% change from the last price of $4.54.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","31":"$31","9.25":"$9.25","16.5":"$16.5","23.75":"$23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$20.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.25,16.5,23.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Dec<br/>2023","12":"Mar<br/>2024","25":"Mar<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.42,6.387692307692308,8.355384615384615,10.323076923076922,12.29076923076923,14.258461538461537,16.226153846153846,18.193846153846152,20.161538461538463,22.129230769230766,24.096923076923076,26.064615384615387,28.03230769230769,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.42,5.656923076923077,6.8938461538461535,8.13076923076923,9.367692307692307,10.604615384615384,11.84153846153846,13.078461538461537,14.315384615384614,15.552307692307691,16.78923076923077,18.026153846153846,19.263076923076923,{"y":20.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.42,4.926153846153846,5.432307692307692,5.938461538461539,6.444615384615385,6.950769230769231,7.456923076923077,7.963076923076923,8.46923076923077,8.975384615384616,9.481538461538461,9.987692307692308,10.493846153846153,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.92,"date":1679616000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.06,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.41,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.03,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.28,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.85,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.42,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$20.50Lowest Price Target$11.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group
Buy
Reiterated
12/13/23
Analysts Offer Insights on Healthcare Companies: NextCure (NASDAQ: NXTC) and Achieve Life Sciences (NASDAQ: ACHV)
Oppenheimer
$18.00
Buy
296.48%
Upside
Assigned
12/12/23
Achieve Life Sciences price target lowered by $3 at Oppenheimer, here's whyAchieve Life Sciences price target lowered by $3 at Oppenheimer, here's why
Alliance Global Partners
$25.00
Buy
450.66%
Upside
Reiterated
11/10/23
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vor Biopharma (NASDAQ: VOR), Gilead Sciences (NASDAQ: GILD) and Achieve Life Sciences (NASDAQ: ACHV)

Best Analysts Covering Achieve Life Sciences

Which Analyst Should I Follow If I Want to Buy ACHV and Sell After:
1 Month
Jason McCarthyMaxim Group
Success Rate
7/14 ratings generated profit
50%
Average Return
+10.83%
reiterated a buy rating 4 months ago
Copying Jason McCarthy's trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +10.83% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Jason McCarthyMaxim Group
Success Rate
7/14 ratings generated profit
50%
Average Return
+14.83%
reiterated a buy rating 4 months ago
Copying Jason McCarthy's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +14.83% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Jason McCarthyMaxim Group
Success Rate
7/14 ratings generated profit
50%
Average Return
+7.99%
reiterated a buy rating 4 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +7.99% per trade.
2 Years
Jason McCarthyMaxim Group
Success Rate
4/14 ratings generated profit
29%
Average Return
-0.09%
reiterated a buy rating 4 months ago
Copying Jason McCarthy's trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of -0.09% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACHV Analyst Recommendation Trends

Rating
Sep 23
Nov 23
Dec 23
Feb 24
Mar 24
Strong Buy
5
9
9
9
5
Buy
0
0
1
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
9
10
10
6
In the current month, ACHV has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ACHV average Analyst price target in the past 3 months is $20.50.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

ACHV Financial Forecast

ACHV Earnings Forecast

Next quarter’s earnings estimate for ACHV is -$0.31 with a range of -$0.35 to -$0.28. The previous quarter’s EPS was -$0.34. ACHV beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.37% of the time in the same period. In the last calendar year ACHV has Outperformed its overall industry.
Next quarter’s earnings estimate for ACHV is -$0.31 with a range of -$0.35 to -$0.28. The previous quarter’s EPS was -$0.34. ACHV beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.37% of the time in the same period. In the last calendar year ACHV has Outperformed its overall industry.
No data currently available

ACHV Sales Forecast

Next quarter’s sales forecast for ACHV is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ACHV beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.05% of the time in the same period. In the last calendar year ACHV has Underperformed its overall industry.
Next quarter’s sales forecast for ACHV is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ACHV beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.05% of the time in the same period. In the last calendar year ACHV has Underperformed its overall industry.

ACHV Stock Forecast FAQ

What is ACHV’s average 12-month price target, according to analysts?
Based on analyst ratings, Achieve Life Sciences Inc’s 12-month average price target is $20.50.
    What is ACHV’s upside potential, based on the analysts’ average price target?
    Achieve Life Sciences Inc has 351.54% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ACHV a Buy, Sell or Hold?
          Achieve Life Sciences Inc has a conensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Achieve Life Sciences Inc’s price target?
            The average price target for Achieve Life Sciences Inc is $20.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $11.00. The average price target represents 351.54% Increase from the current price of $4.54.
              What do analysts say about Achieve Life Sciences Inc?
              Achieve Life Sciences Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of ACHV?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis